Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2024 · View financials
Decision snapshot: CLOV stock price vs BPMC: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BPMC's multiple
Needs BPMC P/S.
Implied fair value · at CLOV's multiple
Needs CLOV P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CLOV FY 2025 (ended Dec 31, 2025) · BPMC FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
CLOVER HEALTH INVESTMENTS, CORP. /DE · implied price per share
Bear
-$2.86
Base
-$3.36
Bull
-$3.87
BLUEPRINT MEDICINES CORPORATION · implied price per share
Bear
$1.09
Base
$1.28
Bull
$1.47
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.13x
0.01x
Net debt / EBITDA
Leverage against operating earnings
0.45x
-4.24x
Cash and equivalents
Liquid reserves on the balance sheet
$78.30M
$102.01M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$40.74M
$1.53M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe CLOV can continue scaling revenue while improving margins and closing the gap to positive operating profitability, then holding or accumulating may make sense because the stock is trading within its historical range and carries manageable leverage; otherwise, BPMC’s superior growth and far higher gross margin make CLOV look less attractive on a quality-adjusted basis.
CLOV is priced on a P/S basis at 1.4x and EV/Revenue at 1.4x, while BPMC does not have comparable valuation multiples provided here, limiting direct relative multiple comparison. CLOV’s current price of $5.28 sits within its historical band of $4.75 to $5.81, suggesting the market is not assigning a large discount or premium to the stock.
Supporting Metrics
